Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of British Columbia

$27,000.00

Pre-clinical Synergy Studies of Combination Therapies Against Seasonal Influenza Viruses

FY 2025-26

Summary
Despite having effective Health Canada (HC) approved vaccines and antiviral treatments, seasonal influenza (INF) continues to account for significant morbidity and mortality annually. The inherent instability and rapid evolution of RNA viruses poses major challenges for public health and the current therapeutic arsenal, making the threat of emerging INF epidemics and pandemics a persistent concern. The longevity of current antiviral treatments is limited due to the reliance on direct-acting antiviral (DAA) monotherapies, which target single viral proteins that are highly subjective to mutation and subsequent resistance to treatment. Although host-directed antivirals (HDA) are less common due to potential cytotoxicity, they provide a unique treatment opportunity by targeting conserved human factors commonly hijacked by viruses. To mitigate concerns of mutation and toxicity, combination therapies using HDAs and DAAs remain a promising route for treating viral infections, as synergistic effects could reduce the concentration of each drug required. My MSc research addresses the validation and synergy studies of different combinations of HC approved DAAs and UBC-patented HDAs, cladoniamide A and alotaketal C, as potential antiviral therapies for currently circulating INF strains. These studies are investigating significant knowledge gaps in the role of biological sex in INF pathogenesis and treatment, and are using physiologically relevant respiratory models, including male and female-derived primary bronchial cells and cell culture models of the human airway epithelium. Ultimately, the pre-clinical exploration of combination therapies has high significance for clinical translation and could have major implications for precision medicine and pandemic preparedness.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572658
Name
Gordon Danielle G
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Pre-clinical Synergy Studies of Combination Therapies Against Seasonal Influenza Viruses
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Combination Therapy; Direct-Acting Antivirals; Host-Directed Antivirals; Host-Virus Interactions; Influenza Viruses; Molecular Virology; Pandemic Preparedness; Seasonal Respiratory Viruses; Sex Differences; Synergy
Abstract
Despite having effective Health Canada (HC) approved vaccines and antiviral treatments, seasonal influenza (INF) continues to account for significant morbidity and mortality annually. The inherent instability and rapid evolution of RNA viruses poses major challenges for public health and the current therapeutic arsenal, making the threat of emerging INF epidemics and pandemics a persistent concern. The longevity of current antiviral treatments is limited due to the reliance on direct-acting antiviral (DAA) monotherapies, which target single viral proteins that are highly subjective to mutation and subsequent resistance to treatment. Although host-directed antivirals (HDA) are less common due to potential cytotoxicity, they provide a unique treatment opportunity by targeting conserved human factors commonly hijacked by viruses. To mitigate concerns of mutation and toxicity, combination therapies using HDAs and DAAs remain a promising route for treating viral infections, as synergistic effects could reduce the concentration of each drug required. My MSc research addresses the validation and synergy studies of different combinations of HC approved DAAs and UBC-patented HDAs, cladoniamide A and alotaketal C, as potential antiviral therapies for currently circulating INF strains. These studies are investigating significant knowledge gaps in the role of biological sex in INF pathogenesis and treatment, and are using physiologically relevant respiratory models, including male and female-derived primary bronchial cells and cell culture models of the human airway epithelium. Ultimately, the pre-clinical exploration of combination therapies has high significance for clinical translation and could have major implications for precision medicine and pandemic preparedness.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gordon, Danielle G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~